Let’s Get Down to Business – Charting Commercial Logistics
8:30 am Innovative Development in Psychiatry to Progress Efficacious Pipelines
Synopsis
- Evaluating the historic challenges in drug development for psychiatric indications
- Exploring new potential in biotech start-ups to push breakthroughs forward
- Outlining integrated translational approach to discovery for later clinical success
9:00 am Development of Next Generation Antipsychotics: Reflecting on the Past to Guide the future
Synopsis
- Major unmet needs in the treatment of psychiatric disorders
- Lessons learned in discovery and development of antipsychotics practiced over the years
- Strategies to develop next generation antipsychotics for addressing unmet needs
9:30 am Panel Discussion: Guiding Development Strategy to Secure Company Longevity
Synopsis
- Mapping the avenues of developing start-up businesses in the competitive landscape
- What are the considerations made by pharmaceutical companies when making acquisitions?
- How can venture partners be mobilized to grant sufficient capital for pipeline development?
10:00 am Morning Break & Networking
Expert Driven Roundtable Discussions
A session focused on trouble-shooting logistics and collective discourse from field leaders to maximize pipeline success
A session focused on trouble-shooting logistics and collective discourse from field leaders to maximize pipeline success
10:45 am Roundtable Discussion: Establishing the Regulatory Baselines for Streamlined Approval Processes
Synopsis
- Balancing the historic requirements of development with the ethical need to progress
- What safety profiles must be demonstrated and what are the biggest concerns?
- How will drug scheduling impact manufacturing and what roadblocks can be mitigated?
11:15 am Roundtable Discussion: Rationalizing Reimbursement & Insurance Policy
Synopsis
- What do the insurers anticipate will be the pattern of renumeration?
- How will the combination of psychotherapy and pharmaceuticals impact expense?
- What meaningful discussions are required to allow for expansion across the US and globally?
11:45 am Roundtable Discussion: The Steps to Commercial Success – Where Shall We Tread?
Synopsis
An interactive session to allow collaborative discourse between industry leaders and decision makers to set actionable targets for business development in the field of psychedelics and beyond.
- Contemplating the commercially viable psychedelic model to strengthen business outcomes
- Optioning optimal service development for efficient scalability to maximize delivery to patients
• Identifying the intellectual property challenges and proposing potential solutions
12:15 pm Lunch & Networking
Understanding the Now & Moving Forward to the Future
1:15 pm CYB004-Modifications to DMT to Enhance its Therapeutic Potential
Synopsis
- DMT is a fast-acting psychedelic, preclinically shown to promote enduring neurobiological changes.
- Preclinical data shows deuterated DMT has improved bioavailability.
- Inhalational delivery provides a controlled method of administration.
1:45 pm Panel Discussion: Psychotherapy & Psychedelics: A Necessary Symbiosis?
Synopsis
- Exploring the link between therapy and pharmaceutical treatment to enhance efficacy
- What are the implications in widespread distribution whilst maintaining product quality?
- What innovations in digital access and environmental features can be implemented to augment sessions?
2:15 pm Psychedelic Drug Discovery in a New Era: Focus on Serotonergic System Mechanisms
Synopsis
- Understanding how to adequately evaluate molecules to guide decision making
- Exploring identification of potential targets to expand research
2:45 pm Investigating the Mechanisms of Psychedelics and Psychedelic- Derivatives in CNS Disorders
Synopsis
- Exploring the fundamental chemistry of tryptamines to understand their actions at the atomic level
- Designing new tryptamines with unique activity at various neuropsychiatric relevant receptors
- Animal studies showing increased efficacy over current psychedelics despite reduced hallucinogenic effects
3:15 pm Afternoon Break & Networking
4:00 pm Non-Hallucinogenic Psychoplastogens
Synopsis
- Appreciating the role of neural plasticity in the sustained therapeutic effects of psychedelics and related compounds
- Exploring medicinal chemistry of known psychedelic compounds to avoid hallucinogenic effects and cardiotoxicity
- Understanding the mechanism of psychedelic-induced neural plasticity
4:30 pm Panel Discussion: Reflection on Hallucinations & Impact on Efficacy to Guide Development
Synopsis
- Is the hallucinatory aspect of psychedelics merely undesirable or mandatory?
- What are the future implications for expansion of 3rd Generation Psychedelics?
- What further research is required to address this fundamental query?